NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.
Edward M. Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Daniel A. Barocas, Rhonda L. Bitting, Alan H. Bryce, Brian F. Chapin, Heather H. Cheng, Anthony V. D’Amico, Neil Desai, Tanya B. Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Shilpa Gupta, Thomas Guzzo, Joseph E. Ippolito, Michael Kuettel, Joshua M. Lang, Tamara L. Lotan, Rana R. McKay, Todd M. Morgan, George J. Netto, Julio M. Pow‐Sang, Robert E. Reiter, Mack Roach, Tyler P. Robin, Stan Rosenfeld, Ahmad Shabsigh, Daniel E. Spratt, Benjamin A. Teply, Jonathan D. Tward, Richard K. Valicenti, J.K. Wong, Ryan A. Berardi, Dorothy A. Shead, Deborah A. Freedman-Cass
Abstract
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, recurrent, and metastatic disease. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. These NCCN Guidelines Insights summarizes much of the panel's discussions for the 4.2022 and 1.2023 updates to the guidelines regarding systemic therapy for metastatic prostate cancer.